A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
||Male and Female Patients
|U.S. Govt. ID:
||Gulam Manji, MD: 646-317-6085 / firstname.lastname@example.org
The purpose of this study is to assess the safety, tolerablility, and effectiveness of pembrolizumab alone or in combination with standard treatment (cisplatin and 5-fluorouracil) for recurrent or metastatic Gastric Cancer or Gastroesophageal Junction Cancer. Participants will be in the study for approximately 24 months.
This study is closed
Gulam Manji, MD, PhD
|Do you suffer from gastric or gastroesophageal junction cancer?